BEGIN:VCALENDAR METHOD:PUBLISH PRODID:Microsoft Exchange Server 2010 VERSION:2.0 BEGIN:VTIMEZONE TZID:tzone://Microsoft/Utc BEGIN:STANDARD DTSTART:16010101T000000 TZOFFSETFROM:+0000 TZOFFSETTO:+0000 END:STANDARD BEGIN:DAYLIGHT DTSTART:16010101T000000 TZOFFSETFROM:+0000 TZOFFSETTO:+0000 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT ORGANIZER;CN=Kate Boehner:mailto:kate.b@jhu.edu DESCRIPTION:Please join us for the weekly Tuberculosis Research Advancement Center (TRAC) Seminar Series from 12:00 – 1:00 PM ET in CRB-2\, 1M.13 o r via Zoom\n\nRSVP for lunch by Wedne sday\, 4/19 at 12pm.\n\n\n\nThursd ay\, April 20th\n\nTRUNCATE-TB Trial\n\n\n[cid:image001.png@01D96E1F.CB089 880]\nNicholas Paton\, MD\, FRCP\nProfessor of Infectious Diseases\, Natio nal University of Singapore\nProfessor of Infectious Diseases\, London Sch ool of Hygiene and Tropical Medicine\nProf. Nicholas Paton trained in Medi cine and Infectious Diseases in Cambridge\, Sydney and London\, and in Epi demiology at the London School of Hygiene and Tropical Medicine. From 1997 to 2005 he worked as Head of Department at the National HIV Referral Cent re in Singapore and\, in addition to clinical care responsibilities\, deve loped a Centre for Research in HIV and Communicable Diseases. From 2006 to 2011 he worked at the UK MRC Clinical Trials Unit where he was the Chief Investigator of large HIV treatment trials such as PIVOT (a trial of a PI- monotherapy strategy done at 45 clinical sites in the UK)\; and EARNEST (t esting options for second-line therapy in over 1200 patients in 5 countrie s in sub-Saharan Africa).\nHe currently holds a joint appointment as Profe ssor of Infectious Diseases at the National University of Singapore and at the London School of Hygiene and Tropical Medicine. He is the Chief Inves tigator of the NADIA trial (comparing dolutegravir with darunavir and comp aring maintenance of tenofovir versus switching to zidovudine in second-li ne therapy\, done in 7 sites in Uganda\, Kenya and Zimbabwe) and the scien tific lead of the CARES trial (comparing long acting cabotegravir/rilpivir ine with standard combination ART at 8 sites in Uganda\, Kenya and South A frica). In Singapore he leads a programme of TB trials focused on trials o f host-directed therapies for TB and exploring novel TB trial outcome meas ures\; and is the Chief Investigator on the TRUNCATE-TB trial (a strategy trial of 2 months of treatment for drug-susceptible TB done across a netwo rk of 18 sites in Asia and Africa).\n\nThe April TRAC Seminar Series is pr esented by the TRAC Clinical Core on “Updates from NAR (The Union – North American R egion) Conference.”\nHave someone that you think should be on the listse rv? Share this link with them to get them on the list:\nhttps://www.survey monkey.com/r/SG377G2\n\nJoin via Zoom:\nTopic: TRAC Seminar Series\nTime: Every week on Thursday at 12:00 PM Eastern Time (US and Canada)\nJoin Zoom Meeting: https://jhjhm.zoom.us/j/92237457953\nDial by your location\n +1 646 558 8656 US (New York)\nMeeting ID: 922 3745 7953\nFind your lo cal number: https://jhjhm.zoom.us/u/aeJ6SHLgpT\n\n\n UID:040000008200E00074C5B7101A82E00800000000964F2952416ED901000000000000000 0100000001C59EE8B5B0848419D3F1AAC26238729 SUMMARY:4/20 TRAC Seminar | TRUNCATE-TB Trial - Nicholas Paton\, MD\, FRCP DTSTART:20230420T160000Z DTEND:20230420T170000Z CLASS:PUBLIC PRIORITY:5 DTSTAMP:20230413T195322Z TRANSP:OPAQUE STATUS:CONFIRMED LOCATION;ALTREP=:Hybrid: Zoom & CRB-2\, 1M.13 X-MICROSOFT-CDO-BUSYSTATUS:BUSY X-MICROSOFT-CDO-INTENDEDSTATUS:BUSY X-MICROSOFT-CDO-ALLDAYEVENT:FALSE X-MICROSOFT-CDO-IMPORTANCE:1 X-MICROSOFT-CDO-INSTTYPE:0 X-MICROSOFT-ONLINEMEETINGEXTERNALLINK: X-MICROSOFT-ONLINEMEETINGCONFLINK: X-MICROSOFT-DONOTFORWARDMEETING:FALSE X-MICROSOFT-DISALLOW-COUNTER:FALSE X-MICROSOFT-LOCATIONDISPLAYNAME:Hybrid: Zoom & CRB-2\, 1M.13 X-MICROSOFT-LOCATIONSOURCE:LocationServices X-MICROSOFT-LATITUDE:0 X-MICROSOFT-LONGITUDE:0 BEGIN:VALARM DESCRIPTION:REMINDER TRIGGER;RELATED=START:-PT15M ACTION:DISPLAY END:VALARM END:VEVENT END:VCALENDAR